Miyoshi H, Baxter M, Kimura T, Hattori M, Morimoto Y, Marinkovich D, Tamiwa M, Hirose T.
A real-world, observational study of the initiation, use, and effectiveness of basal-bolus or premixed insulin in Japanese people with type 2 diabetes.
Diabetes Ther. 2021, in press
IF: 3.179
Tsuchida K, Nakamura A, Miyoshi H, Yang K, Yamauchi Y, Kawata S, Omori K, Takahashi K, Kitao N, Nomoto H, Kameda H, Cho KY, Seino Y, Terauchi Y, Atsumi T.
Glucokinase is required for high-starch diet-induced beta cell mass expansion in mice.
J Diabetes Investig, in press.
IF: 3.761
Shimatsu A, Nakamura A, Takahashi Y, Fujio S, Satoh F, Tahara S, Nishioka H, Takano K, Yamashita M, Arima H, Tominaga A, Tateishi S, Matsushita Y.
Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: A multicenter, single-arm, phase 3 study in Japan.
Endocr J, in press.
IF: 1.952
Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Omori Kazuno, Tsuchida K, Miya A, Shigesawa I, Tsuchida K, Yanagiya S, Kameda H, Yokoyama H, Taneda S, Kurihara Y, Aoki S, Nishimoto N, Atsumi T, Miyoshi H.
Improved Time in Range and Postprandial Hyperglycemia with Canagliflozin in Combination with Teneligliptin: Secondary Analyses of the CALMER study.
Journal of Diabetes Investigation, in press
IF: 3.761
Nomoto H, Oba-Yamamoto C, Takahashi Y, Takeuchi J, Nagai S, Yokoyama H, Taneda S, Kurihara Y, Aoki S, Kameda H, Cho KY, Nakamura A, Atsumi T, Miyoshi H.
Effects of switching from liraglutide or dulaglutide to subcutaneous semaglutide on glucose metabolism and treatment satisfaction in patients with type 2 diabetes: protocol for a multi-center, prospective, randomized, open-label, blinded endpoint parallel-group comparison study (the SWITCH-SEMA 1 study).
Diabetes Ther. 2020, in press
IF: 3.179
Kimura Y, Higuchi I, Kobayashi M, Furugen A, Narumi K, Suzuki Y, Miyoshi H, Nakamura A, Atsumi T, Iseki K.
The association between SLC16A11 haplotype and lipid metabolism in Japanese patients with type 2 diabetes.
Drug Metab Pharmacokinet, in press.
IF: 2.772
Miya A, Nakamura A, Cho KY, Nomoto H, Kawata S, Sugawara H, Takeuchi J, Nagai S, Tsuchida K, Omori K, Yokoyama H, Taneda S, Kurihara S, Aoki S, Atsumi T, Miyoshi H.
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin Journal of Diabetes Investigation, in press
IF: 3.761
Yuno A, Kenmotsu Y, Takahashi Y, Nomoto H, Kameda H, Cho KY, Nakamura A, Yamashita Y, Nakamura J, Nakakubo S, Kamada K, Suzuki M, Sugino H, Inoshita N, Konno S, Miyoshi H, Atsumi T, Sawamura Y, Shimatsu A.
Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia.
Endocrine Journal, in press.
IF: 1.952 (2019)
Takahashi K, Nakamura A, Furusawa S, Yokozeki K, Sugawara H, Yanagisawa H, Akikawa K, Kikuchi H. Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria.
J Clin Transl Endocrinol, 2020 (in press).
IF：なし
